We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.39%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
+$177M
Cap. Flow
-$53.9M
Cap. Flow %
-1.89%
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
42
Reduced
44
Closed
16

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$46M
2
DHR icon
Danaher
DHR
+$34.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$22.3M
5
DXCM icon
DexCom
DXCM
+$20M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$44.2M
2
MRK icon
Merck
MRK
+$39.7M
3
PFE icon
Pfizer
PFE
+$39.7M
4
ABBV icon
AbbVie
ABBV
+$24.5M
5
CNC icon
Centene
CNC
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.34%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOLX
151
DELISTED
Hologic
HOLX
$2.37M 0.08%
32,564
– –
MOR
152
DELISTED
MorphoSys AG American Depositary Shares
MOR
$2.32M 0.08%
81,867
– –
INGN icon
153
Inogen
INGN
$187M
$2.3M 0.08%
51,406
– –
PRGO icon
154
Perrigo
PRGO
$1.49B
$2.29M 0.08%
51,224
– –
XRN
155
Chiron Real Estate Inc
XRN
$465M
$2.28M 0.08%
34,979
– –
BHC icon
156
Bausch Health
BHC
$2.41B
$2.11M 0.07%
101,412
-17,000
-14% -$317K
NCNA
157
NuCana
NCNA
$5.79M
$2.07M 0.07%
92
– –
ALC icon
158
Alcon
ALC
$34.6B
$2.06M 0.07%
31,286
-5,400
-15% -$338K
MTEM
159
DELISTED
Molecular Templates, Inc.
MTEM
$2.06M 0.07%
14,655
– –
HR icon
160
Healthcare Realty
HR
$7.02B
$1.95M 0.07%
70,662
– –
ICPT
161
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.9M 0.07%
77,067
– –
ZGNX
162
DELISTED
Zogenix, Inc.
ZGNX
$1.78M 0.06%
88,977
-244,425
-73% -$5M
HARP
163
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.77M 0.06%
10,642
– –
MIST icon
164
Milestone Pharmaceuticals
MIST
$146M
$1.7M 0.06%
253,610
+40,300
+19% +$270K
GRTS
165
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$1.65M 0.06%
+419,005
New +$1.27M
AVDL
166
DELISTED
Avadel Pharmaceuticals
AVDL
$1.56M 0.05%
233,612
– –
AFMD
167
DELISTED
Affimed
AFMD
$1.56M 0.05%
+26,802
New +$1.26M
DNTH icon
168
Dianthus Therapeutics
DNTH
$6.04B
$1.51M 0.05%
12,027
– –
DRNA
169
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.5M 0.05%
68,150
– –
MDGL icon
170
Madrigal Pharmaceuticals
MDGL
$11.7B
$1.48M 0.05%
13,340
– –
DHC
171
Diversified Healthcare Trust
DHC
$2.13B
$1.47M 0.05%
357,720
– –
SNR
172
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$1.33M 0.05%
256,398
– –
ALLO icon
173
Allogene Therapeutics
ALLO
$656M
$1.21M 0.04%
+48,089
New +$1.57M
XLV icon
174
State Street Health Care Select Sector SPDR ETF
XLV
$41.8B
$1.14M 0.04%
10,055
– –
IMGN
175
DELISTED
Immunogen Inc
IMGN
$1.08M 0.04%
168,190
– –
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Tekla Capital Management held 216 positions worth $2.85B, up 6.6% from $2.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Tekla Capital Management's Q4 2020 filing shows 12 new, 42 increased, 44 reduced and 16 closed positions. Its largest new stake was Teladoc Health: 56,520 shares worth $11.3M. The largest sale was Amgen, an estimated $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2020 buy was Teladoc Health: 56,520 shares worth $11.3M.
  • Tekla Capital Management added most to Thermo Fisher Scientific in Q4 2020, an estimated $46M increase.
  • Tekla Capital Management's biggest Q4 2020 reduction was Amgen, cutting an estimated $44.2M.
  • Tekla Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $19M.
  • Tekla Capital Management's ten largest holdings make up 28% of its $2.85B portfolio in Q4 2020.
  • Tekla Capital Management opened 12 new positions and closed 16 in Q4 2020.
  • Tekla Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.